205 related articles for article (PubMed ID: 34873844)
1. Quinoline-based thiazolidinone derivatives as potent cytotoxic and apoptosis-inducing agents through EGFR inhibition.
Nafie MS; Kishk SM; Mahgoub S; Amer AM
Chem Biol Drug Des; 2022 Apr; 99(4):547-560. PubMed ID: 34873844
[TBL] [Abstract][Full Text] [Related]
2. N-allyl quinoxaline derivative exhibited potent and selective cytotoxicity through EGFR/VEGFR-mediated apoptosis: In vitro and in vivo studies.
Nafie MS; Ali MA; Youssef MM
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23690. PubMed ID: 38493304
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
Shaheen MA; El-Emam AA; El-Gohary NS
Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
[TBL] [Abstract][Full Text] [Related]
4. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents.
Kamboj P; Anjali ; Imtiyaz K; Rizvi MA; Nath V; Kumar V; Husain A; Amir M
Sci Rep; 2024 Apr; 14(1):8457. PubMed ID: 38605072
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
8. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
[TBL] [Abstract][Full Text] [Related]
10. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
11. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
12. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
[TBL] [Abstract][Full Text] [Related]
14. Hydrazinecarbonyl-thiazol-2-acetamides with pronounced apoptotic behavior: synthesis, in vitro/in vivo anti-proliferative activity and molecular modeling simulations.
Elsayed RW; Bayoumi SM; El-Subbagh HI; El-Sayed SM
Bioorg Med Chem Lett; 2023 May; 87():129285. PubMed ID: 37054758
[TBL] [Abstract][Full Text] [Related]
15. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
[No Abstract] [Full Text] [Related]
16. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.
Kardile RA; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Thopate SR
Eur J Med Chem; 2023 Jan; 245(Pt 1):114889. PubMed ID: 36375337
[TBL] [Abstract][Full Text] [Related]
18. New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study.
Mansour NI; El-Sayed SM; El-Gohary NS; Abdel-Aziz NI; El-Subbagh HI; Ghaly MA
Bioorg Chem; 2022 Oct; 127():105966. PubMed ID: 35728294
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and molecular modeling of quinoline-based derivatives as anti-breast cancer agents targeting EGFR/AKT signaling pathway.
Batran RZ; El-Daly SM; El-Kashak WA; Ahmed EY
Chem Biol Drug Des; 2022 Mar; 99(3):470-482. PubMed ID: 34939319
[TBL] [Abstract][Full Text] [Related]
20. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR
Abo Al-Hamd MG; Tawfik HO; Abdullah O; Yamaguchi K; Sugiura M; Mehany ABM; El-Hamamsy MH; El-Moselhy TF
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241674. PubMed ID: 37548154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
